Drug company CEO slams CNBC

Source: Business Insider

Martin Shkreli, the hedge fund manager who triggered an outcry by putting a 5,000 percent markup on its lifesaving drug, has gone to war with business news channel CNBC, reports Dylan Byers of CNNMoney.

Byers writes, “According to CNBC host Scott Wapner, Shkreli wanted to come on CNBC to defend another drug company, Valeant Pharmaceuticals, against accusations of accounting fraud. CNBC told Shkreli they would also have to talk to him about the elephant in the room — his decision to jack up the price of the toxoplasmosis drug Daraprim from $18 a pill to $750 a pill. He said no.

“Shkreli tells a slightly different version: CNBC had asked him to come on and talk about Valeant, then said they wanted to talk about Turing Pharmaceuticals as well. ‘I tell them to pound sand,’ Shkreli wrote on Twitter.

“Shkreli instead went to Fox Business Network on Friday morning, where he defended his price gouging in an interview with Maria Bartiromo.”

Read more here.

Chris Roush

Chris Roush was the dean of the School of Communications at Quinnipiac University in Hamden, Connecticut. He was previously Walter E. Hussman Sr. Distinguished Professor in business journalism at UNC-Chapel Hill. He is a former business journalist for Bloomberg News, Businessweek, The Atlanta Journal-Constitution, The Tampa Tribune and the Sarasota Herald-Tribune. He is the author of the leading business reporting textbook "Show me the Money: Writing Business and Economics Stories for Mass Communication" and "Thinking Things Over," a biography of former Wall Street Journal editor Vermont Royster.

Next Reno business reporter is retiring »

Previous « Inside Business publisher to retire

View Comments

tim says:
October 25, 2015 at 11:41 am
If this doofus doesn't yet realize that he will always be asked about daraprim, and that it will be in the first sentence of his obituary, he is far too stupid to run any hedge fund that includes my money. Some acts simply define us, sir.